Phase I Study to Evaluate the Safety, Tolerability, PK and Pharmacodynamics of 3 Dosages of Estetrol, the Lowest Dose of 2 mg Estetrol Compared With 2 mg of E2, After Daily Oral Administration for 28 Days in Healthy Postmenopausal Women.

Trial Profile

Phase I Study to Evaluate the Safety, Tolerability, PK and Pharmacodynamics of 3 Dosages of Estetrol, the Lowest Dose of 2 mg Estetrol Compared With 2 mg of E2, After Daily Oral Administration for 28 Days in Healthy Postmenopausal Women.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2012

At a glance

  • Drugs Estetrol; Estradiol
  • Indications Menopausal syndrome
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jun 2011 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.
    • 28 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top